tiprankstipranks
Trending News
More News >
Treace Medical Concepts (TMCI)
NASDAQ:TMCI
US Market
Advertisement

Treace Medical Concepts (TMCI) Earnings Dates, Call Summary & Reports

Compare
111 Followers

Earnings Data

Report Date
Feb 26, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.1
Last Year’s EPS
-0.01
Same Quarter Last Year
Based on 6 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call reflected both positive and negative aspects. While there was notable revenue growth and improved adjusted EBITDA, challenges such as a revised revenue outlook, pressure on Lapiplasty volumes, and economic impacts on elective procedures were significant.
Company Guidance
During the third quarter of 2025 earnings call, Treace Medical outlined several key metrics and strategic adjustments in response to market dynamics. The company reported Q3 revenues of $50.2 million, marking an 11% increase over Q3 2024, driven by an increase in bunion procedure kits sold. Despite this revenue growth, the company experienced a net loss of $16.3 million, or $0.26 per share, a 6% increase from the previous year. Adjusted EBITDA loss improved by 49% to $2.6 million compared to Q3 2024. The company revised its full-year revenue guidance to $211 million to $213 million, indicating a modest growth of 1% to 2% over 2024. The call highlighted a strategic shift to address surgeon preferences for minimally invasive osteotomies, which has impacted Lapiplasty volumes. To mitigate this, Treace has launched three new bunion correction systems and anticipates case volume growth, although at lower ASPs. The company also noted a $6 million benefit from sales to stocking distributors in Q3, with $3 million expected to be a headwind in Q4. Looking ahead, Treace plans to focus on expanding its product portfolio, increasing surgeon training, and enhancing its sales team's capabilities to drive market share and profitability in 2026. Total liquidity stood at $80.6 million as of September 30, 2025.
Revenue Growth
The company reported third quarter revenues of $50.2 million, representing 11% growth over the third quarter of 2024.
Adjusted EBITDA Improvement
Adjusted EBITDA improved by 49% compared to the prior year, with a third quarter adjusted EBITDA loss of $2.6 million compared to $5.1 million in Q3 2024.
Expansion of Product Portfolio
Treace Medical has developed and commercialized 3 new bunion correction systems, broadening their product offerings to address nearly 100% of surgeon preferences for bunion correction.
Sales Team Expansion
The company brought on a Chief Commercial Officer and a new Senior Vice President of Sales, adding leading foot and ankle sales experts to their sales team.
Increased Liquidity
Total liquidity as of September 30, 2025, was $80.6 million, marking a decrease in cash usage by 17% in Q3 2025 compared to the prior year.

Treace Medical Concepts (TMCI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

TMCI Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 26, 2026
2025 (Q4)
-0.10 / -
-0.01
Nov 06, 2025
2025 (Q3)
-0.28 / -0.26
-0.25-4.00% (-0.01)
Aug 07, 2025
2025 (Q2)
-0.29 / -0.28
-0.3417.65% (+0.06)
May 08, 2025
2025 (Q1)
-0.30 / -0.25
-0.316.67% (+0.05)
Feb 27, 2025
2024 (Q4)
-0.04 / -0.01
-0.190.00% (+0.09)
Nov 05, 2024
2024 (Q3)
-0.27 / -0.25
-0.2810.71% (+0.03)
Aug 06, 2024
2024 (Q2)
-0.29 / -0.34
-0.2-70.00% (-0.14)
May 07, 2024
2024 (Q1)
-0.30 / -0.30
-0.23-30.43% (-0.07)
Feb 27, 2024
2023 (Q4)
-0.09 / -0.10
-0.08-25.00% (-0.02)
Nov 09, 2023
2023 (Q3)
-0.26 / -0.28
-0.22-27.27% (-0.06)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

TMCI Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2025
$6.23$4.46-28.41%
Aug 07, 2025
$5.68$6.13+7.92%
May 08, 2025
$7.54$6.82-9.55%
Feb 27, 2025
$9.13$8.94-2.08%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Treace Medical Concepts (TMCI) report earnings?
Treace Medical Concepts (TMCI) is schdueled to report earning on Feb 26, 2026, After Close (Confirmed).
    What is Treace Medical Concepts (TMCI) earnings time?
    Treace Medical Concepts (TMCI) earnings time is at Feb 26, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is TMCI EPS forecast?
          TMCI EPS forecast for the fiscal quarter 2025 (Q4) is -0.1.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis